Sector News

Valeant may raise Allergan bid, says it won’t walk away

October 20, 2014
Life sciences
(Reuters) – Valeant Pharmaceuticals Inc (VRX.TO) may raise its hostile takeover bid for Allergan Inc (AGN.N) and will not walk away from its pursuit ahead of Allergan’s Dec. 18 special shareholder meeting, Chief Executive Michael Pearson said on Monday.
 
Pearson also said speculation that Valeant’s relationship was strained with Pershing Square Capital Management, Allergan’s biggest shareholder, is false.
 
(Reporting by Rod Nickel in Winnipeg, Manitoba Editing by W Simon)

Related News

April 17, 2021

Thermo Fisher to buy research contractor PPD in $17B deal

Life sciences

Thermo Fisher Scientific plans to buy PPD for $17.4 billion to bolster its clinical research service offerings to pharmaceutical and biotech companies.

April 17, 2021

Nestlé finds supplement cocktail slashes preterm birth in major preconception study

Life sciences

Nestlé Research has linked a specific blend of myo-inositol (a type of sugar), probiotics, riboflavin, zinc and vitamins D, B6 and B12 to the decreased incidence of preterm birth when consumed before and during pregnancy.

April 17, 2021

Eli Lilly, riding pharma’s rising digital wave, drafts Apple exec to replace Shah as CDO

Life sciences

Eli Lilly hired a new digital chief from Apple in another consumer switch for pharma and as the industry speeds up its shift to online strategies.

Send this to a friend